Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab combinations in B-cell non-Hodgkin lymphoma
2023-504805-35-00Phase 2Authorised
- Sponsor
- Genmab
- Start
- Oct 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 2, open-label trial of epcoritamab in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (10 arms), sponsored by Genmab. Primary endpoints: Incidence of dose-limiting toxicities, Incidence and severity of adverse events and 3 more. Planned start Oct 2020; status: authorised.
02
Drugs
epcoritamab
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2023-504805-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504805-35-00.